Cargando…

Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates

BACKGROUND: Olanzapine, regarded as one of the most efficacious antipsychotic medications for the treatment of schizophrenia, is associated with a high risk of weight gain and metabolic dysfunction. ALKS 3831, a clinical candidate for treatment of schizophrenia, is a combination of olanzapine and sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Cunningham, Jacobi I, Eyerman, David J, Todtenkopf, Mark S, Dean, Reginald L, Deaver, Daniel R, Sanchez, Connie, Namchuk, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764014/
https://www.ncbi.nlm.nih.gov/pubmed/31294646
http://dx.doi.org/10.1177/0269881119856850
_version_ 1783454286922907648
author Cunningham, Jacobi I
Eyerman, David J
Todtenkopf, Mark S
Dean, Reginald L
Deaver, Daniel R
Sanchez, Connie
Namchuk, Mark
author_facet Cunningham, Jacobi I
Eyerman, David J
Todtenkopf, Mark S
Dean, Reginald L
Deaver, Daniel R
Sanchez, Connie
Namchuk, Mark
author_sort Cunningham, Jacobi I
collection PubMed
description BACKGROUND: Olanzapine, regarded as one of the most efficacious antipsychotic medications for the treatment of schizophrenia, is associated with a high risk of weight gain and metabolic dysfunction. ALKS 3831, a clinical candidate for treatment of schizophrenia, is a combination of olanzapine and samidorphan, an opioid receptor antagonist. The addition of samidorphan is intended to mitigate weight gain and the metabolic dysregulation associated with the use of olanzapine. METHODS: Non-clinical studies were conducted to assess the metabolic effects of olanzapine and samidorphan alone and in combination at clinically relevant exposure levels. RESULTS: Chronic olanzapine administration in male and female rats shifted body composition by increasing adipose mass, which was accompanied by an increase in the rate of weight gain in female rats. Co-administration of samidorphan normalized body composition in both sexes and attenuated weight gain in female rats. In hyperinsulinemic euglycemic clamp experiments conducted prior to measurable changes in weight and/or body composition, olanzapine decreased hepatic insulin sensitivity and glucose uptake in muscle while increasing uptake in adipose tissue. Samidorphan appeared to normalize glucose utilization in both tissues, but did not restore hepatic insulin sensitivity. In subsequent studies, samidorphan normalized olanzapine-induced decreases in whole-body glucose clearance following bolus insulin administration. Results from experiments in female monkeys paralleled the effects in rats. CONCLUSIONS: Olanzapine administration increased weight gain and adiposity, both of which were attenuated by samidorphan. Furthermore, the combination of olanzapine and samidorphan prevented olanzapine-induced insulin insensitivity. Collectively, these data indicate that samidorphan mitigates several metabolic abnormalities associated with olanzapine in both the presence and the absence of weight gain.
format Online
Article
Text
id pubmed-6764014
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-67640142019-10-22 Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates Cunningham, Jacobi I Eyerman, David J Todtenkopf, Mark S Dean, Reginald L Deaver, Daniel R Sanchez, Connie Namchuk, Mark J Psychopharmacol Original Papers BACKGROUND: Olanzapine, regarded as one of the most efficacious antipsychotic medications for the treatment of schizophrenia, is associated with a high risk of weight gain and metabolic dysfunction. ALKS 3831, a clinical candidate for treatment of schizophrenia, is a combination of olanzapine and samidorphan, an opioid receptor antagonist. The addition of samidorphan is intended to mitigate weight gain and the metabolic dysregulation associated with the use of olanzapine. METHODS: Non-clinical studies were conducted to assess the metabolic effects of olanzapine and samidorphan alone and in combination at clinically relevant exposure levels. RESULTS: Chronic olanzapine administration in male and female rats shifted body composition by increasing adipose mass, which was accompanied by an increase in the rate of weight gain in female rats. Co-administration of samidorphan normalized body composition in both sexes and attenuated weight gain in female rats. In hyperinsulinemic euglycemic clamp experiments conducted prior to measurable changes in weight and/or body composition, olanzapine decreased hepatic insulin sensitivity and glucose uptake in muscle while increasing uptake in adipose tissue. Samidorphan appeared to normalize glucose utilization in both tissues, but did not restore hepatic insulin sensitivity. In subsequent studies, samidorphan normalized olanzapine-induced decreases in whole-body glucose clearance following bolus insulin administration. Results from experiments in female monkeys paralleled the effects in rats. CONCLUSIONS: Olanzapine administration increased weight gain and adiposity, both of which were attenuated by samidorphan. Furthermore, the combination of olanzapine and samidorphan prevented olanzapine-induced insulin insensitivity. Collectively, these data indicate that samidorphan mitigates several metabolic abnormalities associated with olanzapine in both the presence and the absence of weight gain. SAGE Publications 2019-07-11 2019-10 /pmc/articles/PMC6764014/ /pubmed/31294646 http://dx.doi.org/10.1177/0269881119856850 Text en © The Author(s) 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Papers
Cunningham, Jacobi I
Eyerman, David J
Todtenkopf, Mark S
Dean, Reginald L
Deaver, Daniel R
Sanchez, Connie
Namchuk, Mark
Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates
title Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates
title_full Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates
title_fullStr Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates
title_full_unstemmed Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates
title_short Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates
title_sort samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates
topic Original Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764014/
https://www.ncbi.nlm.nih.gov/pubmed/31294646
http://dx.doi.org/10.1177/0269881119856850
work_keys_str_mv AT cunninghamjacobii samidorphanmitigatesolanzapineinducedweightgainandmetabolicdysfunctioninratsandnonhumanprimates
AT eyermandavidj samidorphanmitigatesolanzapineinducedweightgainandmetabolicdysfunctioninratsandnonhumanprimates
AT todtenkopfmarks samidorphanmitigatesolanzapineinducedweightgainandmetabolicdysfunctioninratsandnonhumanprimates
AT deanreginaldl samidorphanmitigatesolanzapineinducedweightgainandmetabolicdysfunctioninratsandnonhumanprimates
AT deaverdanielr samidorphanmitigatesolanzapineinducedweightgainandmetabolicdysfunctioninratsandnonhumanprimates
AT sanchezconnie samidorphanmitigatesolanzapineinducedweightgainandmetabolicdysfunctioninratsandnonhumanprimates
AT namchukmark samidorphanmitigatesolanzapineinducedweightgainandmetabolicdysfunctioninratsandnonhumanprimates